FDA Approves Unknown Drug — CHANGZHOU PHARM
CHANGZHOU PHARM received FDA approval for its application ANDA221019 on November 5, 2026, signaling a significant entry into the pharmaceutical market that will likely provide safer, more accessible alternatives for patients and intensify competitive pressure on existing brand-name products.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed